| Literature DB >> 29865161 |
Byeong Hwa Yun1, Jingshu Guo2, Robert J Turesky3.
Abstract
The measureies">ment of DNA adducts provides imEntities:
Keywords: DNA adducts; biomarker; biomonitoring; carcinogen; formalin-fixed paraffin-embedded tissues; mass spectrometry
Year: 2018 PMID: 29865161 PMCID: PMC6027047 DOI: 10.3390/toxics6020030
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Figure 1The metabolic activation of aristolochic acid I (AA-I), 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), 5-methylchrysene, and tamoxifen are shown as prototypes of procarcinogens. Bioactivation is carried out with phase I and/or phase II enzymes, which lead to the formation of DNA adducts. AA-I undergoes nitro-reduction through NAD(P)H:quinone oxidoreductase (NQO1), cytochrome P450s 1A1 and 1A2, NADPH:P450 reductase (POR) or prostaglandin H synthase (COX). The resulting N-hydroxyaristolactam-I is bioactivated by SULTs to form an unstable N-sulfoxy ester, which quickly undergoes heterolytic cleavage to produce the reactive nitrenium/carbenium intermediate that forms dA-AL-I and other DNA adducts. PhIP undergoes N-hydroxylation by P450s, then it is further bioactivated by NATs or SULTs to form N-acetoxy or N-sulfoxy esters, which lead to the formation of dG-C8-PhIP through the nitrenium intermediate. 5-Methylchrysene undergoes epoxidation (P450s 1A1 and 1B1) followed by epoxide hydroxylation (epoxide hydrolase) on the bay-region phenyl ring, to form the corresponding trans-1,2-dihydrodiol-5-methylchrysene. A subsequent round of monooxygenation leads to the formation of anti-1,2-dihydrodiol-3,4-epoxide-5-methylchrysene, which can form a DNA adduct at the N2-atom of dG (dG-N2-5-methylchrysene-diolepoxide). Two pathways are involved in the DNA adduct formation of the bioactivated tamoxifen. In the first pathway, oxidation of the allylic ethyl side chain results in the formation of α-hydroxytamoxifen. The subsequent esterification catalyzed by SULTs leads to the reactive carbenium intermediate and the dG-N2-α-hydroxytamoxifen adduct. The second pathway involves aryl-oxidation of one of the phenyl rings to yield 4-hydroxytamoxifen quinone methide, a reactive electrophile that can form the DNA adducts. Both pathways lead to (Z)- or (E)-dG-N2-4-hydroxytamoxifen.
Figure 2The fragmentation pathways of modified nucleosides analyzed by LC-MS. (A) The major fragmentation of the modified nucleosides is the neutral loss of deoxyribose. Other common fragmentations include (B) the neutral loss of base and (C) the neutral loss of the adduct with the formation of base ions [58].
Figure 3The reactions of formaldehyde mediated crosslinking of DNA and protein. Formaldehyde diffuses through tissue and reacts with a nucleophilic sites of protein and/or DNA base resulting in unstable intermediates of methylol and Schiff base. Then, a second nucleophile from inter- or intramolecular DNA or protein attacks the Schiff base resulting in a crosslinked complex. A specific example of a protein-DNA crosslink is shown. The atoms are color coded: cyan, protein; red, formaldehyde; and black, DNA. Reproduced with permission from [65]. Copyright ASBMB, 2015.
Examples of DNA adducts detected in FFPE tissues.
| Detection Methods | DNA Adducts Detected | Tissues | LOD | References |
|---|---|---|---|---|
|
| 4-ABP-DNA | Human bladder | NR a | [ |
| PAH-DNA | Human breast | NR a | [ | |
| Human esophagus | NR a | [ | ||
| Human prostate | 8 | [ | ||
| Human cervix | 20 | [ | ||
| Human vulva | 8 | [ | ||
| Human placenta | 20 | [ | ||
| DMAB-DNA | Rat multiple tissues | NR a | [ | |
| PhIP-DNA | Human prostate tissue transplanted to mice | NR b | [ | |
| Rat multiple tissues | NR b | [ | ||
| 8-OHdG | Mouse pulmonary epithelial cells | NR a | [ | |
| Tamoxifen-DNA | Rat hepatocytes | 10 | [ | |
|
| B[ | Rat multiple tissues | NR c | [ |
|
| dA-AL-I | Mouse liver and kidney, human kidney | 0.1 | [ |
| dG-C8-4-ABP/PhIP, dG- | Rodent multiple tissues | 0.2–0.5 | [ | |
|
| dG-C8-PhIP | Human prostate | 0.13 | [ |
| dG-C8-4-ABP | Human bladder | 0.2 | [ |
a Adduct levels were reported as relative nuclear stain intensity; b Adduct levels were reported as a percentage of positive cells; c LOD was reported in the citation, which was one per 1010 nucleotides employing 10 µg DNA. NR: Not reported.
Figure 4Mean level of dA-AL-I adducts present in mouse kidney and liver following treatment with AA-I (0.001−1 mg/kg body weight). Adduct levels measured in freshly frozen and FFPE mouse kidney (○ and ●) and liver (□ and ■) (mean adduct level, SD, N = 4 animals per dose, quadruplicate measurements per animal) were plotted as a function of dose. The overall mean difference in adduct levels between freshly frozen and FFEP kidney and liver tissues across all doses was 21 ± 14% (mean ± SD). dA-AL-I adduct formation was below the limit of detection in liver of mice dosed with AA-I at 0.001 mg/kg body weight. Mean levels of dA-AL-I adducts were significantly statistically different between freshly frozen and FFPE kidney or liver at the following dose treatments of AA-I: kidney, 1 mg/kg, p = 0.03; liver, 0.1 mg/kg, p = 0.01; unpaired two-tailed t-test. Reproduced with permission from [104]. Copyright ACS, 2013.
Figure 5Structures, names, and abbreviations of carcinogens and their adducts used for quantitation of multiclass carcinogenic DNA adducts in freshly frozen and FFPE tissues of rodents. Reproduced with permission from [105]. Copyright ACS, 2016.
Figure 6Extracted ion chromatograms of dA-AL-I from human kidney cortex of patients with upper urothelial cancer from Taiwan at levels (A) below the LOQ, and positive samples at (B) 0.4 adducts, and (C) 5.9 adducts per 108 bases. The product ion spectra of dA-AL-I obtained from panel C is depicted in (D) along with the internal standard [15N5]-dA-AL-I (E, 15N labels of the internal standard of dA-AL-I are depicted with asterisks). Insert (F) dA-AL-I adduct levels in matching fresh frozen and FFPE kidney samples, containing both renal cortex and medulla, obtained from 11 individuals residing in endemic regions of Croatia and Serbia who underwent nephroureterectomy for upper urothelial cancer. Reproduced with permission from [104]. Copyright ACS, 2013.
Figure 7Extracted ion chromatograms of dG-C8-PhIP and 13C-labeled dG-C8-PhIP of DNA from fresh frozen and FFPE human prostate tissues at the MS3 scan stage. (A) Fresh frozen prostate and (B) paired FFPE block of a patient who was negative for dG-C8-PhIP; (C) fresh frozen prostate and (D) paired FFPE block of a patient who was positive dG-C8-PhIP at MS3 scan stage. The structure and proposed fragmentation mechanism of aglycone of dG-C8-PhIP are depicted fresh frozen prostate and (D) paired FFPE block of a patient who was positive for dG-C8-PhIP. (E) The product ion spectra at MS3 of unlabeled and 13C-labeled dG-C8-PhIP are shown. (F) Levels of dG-C8-PhIP in paired fresh frozen prostate and FFPE blocks of six patients are shown in (G). The levels of adducts are reported as adducts per 108 nucleotides. * p < 0.05; n.s., statistically not significant. Reproduced with permission from [108]. Copyright ACS, 2017.
Figure 8Scheme of FFPE tissue processing for DNA adduct measurements. DNA is extracted from section cuts or excised whole tissues by the FFPE Miniprep kit (Zymo Research) or Promega Maxwell® automated system. After nuclease digestion, the DNA adducts are measured by UPLC-ESI-IT-MS3. The estimated times of the different processes are reported.